Thrombolytic therapy for acute ischemic stroke: The likelihood of being helped versus harmed

Stroke

Volumn 38, Issue 8, 2007, Pages 2215-2216

  Demaerschalk, Bart M ^a  

^a MAYO CLINIC HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG FATALITY; EDITORIAL; FIBRINOLYTIC THERAPY; HEALTH SURVEY; HUMAN; MORTALITY; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; ACUTE DISEASE; BRAIN ISCHEMIA; CHEMICALLY INDUCED DISORDER; CLINICAL PROTOCOL; EMERGENCY HEALTH SERVICE; INFORMED CONSENT; NOTE; RISK ASSESSMENT; STANDARD; STATISTICS;

ACUTE DISEASE; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL PROTOCOLS; EMERGENCY MEDICAL SERVICES; HUMANS; INFORMED CONSENT; RISK ASSESSMENT; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 34548260328     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.107.494112     Document Type: Editorial

References (10)

1. Brown DL, Barsan WG, Lisabeth LD, Gallery ME, Morgenstern LB. Survey of emergency physicians about recombinant tissue plasminogen activator for acute ischemic stroke. Ann Emerg Med. 2005;46:56-60.
2. tPA for stroke - potential benefit, risk, and alternatives; education tool. Available at: http://aaem.org/education/tpaedtool-AAEM.pdf. Accessed May 22, 2007.
3. Guyatt GG, Rennie D, eds. Users' Guides to the Medical Literature: A Manual for Evidence-Based Practice. Chicago, Ill: American Medical Association Press; 2002: 680.
4. Berger C, Fiorelli M, Steiner T, Schabitz WR, Bozzao L, Bluhmki E, Hacke W, von Kummer R. Hemorrhagic transformation of ischemic brain tissue: asymptomatic or symptomatic? Stroke. 2001;32:1330-1335.
5. von Kummer R. Brain hemorrhage after thrombolysis: good or bad? Stroke. 2002;33:1446-1447.
6. Khatri P, Wechsler LR, Broderick JP. Intracranial hemorrhage associated with revascularization therapies. Stroke. 2007;38:431-440.
7. Position statement on the use of intravenous thrombolytic therapy in the treatment of stroke. Available at: http://www.aaem.org/positionstatements/ thrombolytictherapy.php. Accessed July 5, 2007.
8. Saver JL. Hemorrhage after thrombolytic therapy for stroke: the clinically relevant number needed to harm. Stroke. 2007;38:2279-2283.
9. Saver JL. Number needed to treat estimates incorporating effects over the entire range of clinical outcomes: novel derivation method and application to thrombolytic therapy for acute stroke. Arch Neurol. 2004;61:1066-1070.
10. Burneo JG, Wiebe S. Chapter 3: Outcome and adverse effect measures in neurology. In: Candelise L, Hughes R, Liberati A, Uitdehaag BMJ, Warlow C, eds. Evidence-Based Neurology, Management of Neurological Disorders. Oxford, UK: Blackwell Publishing, BMJI Books; 2007: 20.